GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, a first-in-class oral pyruvate kinase M2 (PKM2) modulator for atopic dermatitis. The drug demonstrated safety, tolerability, target engagement, and evidence of systemic immunomodulation with reduced CCL17/TARC biomarker levels. A Phase 1b trial in adults with moderate to severe atopic dermatitis is underway with data expected by year-end 2026.

First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026

GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.

GSK Targets China's Hepatitis B Market Through New Deal

Investor with bios & tech focus. Tweets are my opinions only and not investment advice. May have positions short or long term on stocks I tweet.

GlaxoSmithKline PLC ADR (GSK) Stock Price, Analysis & Trade Signals